Objective: To estimate the cost-effectiveness of intravenous linezolid as a first-line agent against intravenous vancomycin in treating methicillin-resistant Staphylococcus aureus-confirmed nosocomial pneumonia in four Chinese cities. Methods: A decision-analytic model of 4-week time horizon was used to conduct costeffectiveness analyses from the payer's perspective. Clinical outcomes and resource use data were derived from a head-to-head trial, supplemented with local cost estimates based on hospital data via an expert panel. A series of scenario analyses were conducted to evaluate the impact of uncertainty around model inputs. All results were reported in 2012 Chinese Renminbi. Results: The predicted probability of overall treatment success was 0.629 and 0.602 for linezolid and vancomycin, respectively. Total inpatient costs varied across the four cities, ranging from ¥58,835 to ¥86,894 for linezolid and ¥58,390 to ¥87,033 for vancomycin, respectively. Linezolid was demonstrated to be a dominant treatment strategy in Guangzhou. In Beijing, Nanjing, and Xi'an, incremental cost-effectiveness ratios in terms of additional successfully treated patient were ¥1,861, ¥163, and ¥16,509, respectively. Dominance by linezolid was observed in some scenario analyses with parameters such as treatment duration, inclusion of cost of managing adverse events, and drug acquisition costs being the main drivers of cost-effectiveness results. Conclusions: Despite linezolid's higher drug acquisition cost, its superior clinical efficacy renders it a likely cost-effective alternative for the treatment of methicillinresistant Staphylococcus aureus-confirmed nosocomial pneumonia as compared with branded vancomycin from the payer perspectives of Beijing, Guangzhou, Nanjing, and Xi'an.
Introduction
Nosocomial pneumonia (NP) caused by Staphylococcus aureus is the most commonly observed infection within the hospital setting in the United States, Europe, and Asia including China [1] , with increasing evidence of resistance to methicillin [2, 3] . In a review based on published clinical studies conducted in Europe, the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in clinical settings could be as high as approximately one-third of all clinical isolates of S aureus [4] . In another study with a special focus on ventilator-associated pneumonia, a rate of up to 80% was reported [5] . In China, a study concluded a mean MRSA prevalence of 50.4%, with the highest in Shanghai (80.3%), followed by Beijing (55.5%) and Shenyang (50.0%) [6] . MRSA infections are associated with considerable attributable mortality and morbidity resulting in high health care burden [7, 8] .
Vancomycin has always been a standard treatment for MRSA infection [9] . The presence of vancomycin-intermediate S aureus, however, has become increasingly more common [10, 11] . Concerns over its nephrotoxicity, inadequate penetration into lungs, and the need for intravenous (IV) administration may limit its use.
Linezolid is an oxazolidinone antibiotic and has a unique mechanism of action that inhibits bacterial protein synthesis at an early stage of the process. Because of its unique mechanism of action, cross-resistance with other antimicrobials does not develop easily [12] . In addition, the oral bioavailability of linezolid is almost 100% [13] , thus allowing IV to oral therapy switch without changing the antibacterial agent or dosage regimen.
Compared with vancomycin, linezolid is relatively new and has been approved in China for the treatment of skin and soft tissue infections and hospital-acquired and community-acquired pneumonia. Superior efficacy of linezolid compared with vancomycin was demonstrated in a recently published head-to-head MRSA NP clinical study by Wunderink et al. [14] .
Previous cost-effectiveness studies showed that linezolid was cost-effective compared with vancomycin in treating NP across different country settings, such as Brazil [15] , Germany [16] , Spain [17] , and the United States [18, 19] . To our knowledge and through a review of literature, there has not been any published costeffectiveness study comparing linezolid against vancomycin in a Chinese setting. This study attempted to fill this gap by evaluating the cost-effectiveness of linezolid against vancomycin in treating MRSA confirmed NP from a payer's perspective across four geographically representative Chinese cities-Beijing, Nanjing, Guangzhou, and Xi'an-given that there exist wide variations in affordability as measured by gross domestic product per capita and in health care cost across different regions in China. Despite the fact that cost-effectiveness analysis is not currently formally required in the evaluation process for national reimbursement drug listing, a single cost-effectiveness threshold may not be applicable in the context of China.
Methods

Overall Model Description
A decision-analytic model was developed to estimate relevant costs and health outcomes of linezolid or vancomycin for hospitalized patients with MRSA-confirmed NP. Clinical and resource use parameters used in this study were identified from the Wunderink et al. [14] trial and its subsequent post hoc published analysis [20] , while the local resource use and cost data were provided through review of local published literature and surveys with local clinicians who were experienced in managing MRSA confirmed NP. The incremental costeffectiveness ratio (ICER) in terms of additional successfully treated patient was performed in the context of each city included in this study.
Cost-Effectiveness Model Structure
The model starts with a hypothetical patient for suspected or confirmed gram positive NP (Fig. 1) . The empirical treatment with IV vancomycin or linezolid was considered for a period of 2 days before culture results were available. On MRSA confirmation with laboratory results, the patient was placed on first-line treatment with linezolid or vancomycin for up to a maximum of 14 days. Possible outcomes of first-line treatment were: 1) treatment success (resolution of symptoms or clinical improvement); 2) treatment failure due to lack of efficacy; 3) discontinuation due to adverse events (AEs); and 4) death. In case of treatment failure or discontinuation caused by AEs, the patient was switched to second-line treatment on day 7 of the first-line treatment. The same maximum therapy duration of 14 days was assumed for second-line treatment. The model also included an additional hospital stay of 1.7 and 2 days in the event of adverse event or treatment failure, respectively, based on the post hoc data analysis of Wunderink et al. trial [20] and inputs from local clinical experts. Because of lack of relevant published data, clinical inputs for second-line treatment were assumed to be the same as those of the first-line treatment, which were primarily obtained from the Wunderink et al. [14] trial. Consistent with previously published NP economic models [19, 21] , third-line treatment was not considered in this study because it was believed that most of the relevant costs and outcomes would be captured in the first and second lines of treatments. In accordance with the feedback from local clinical experts, patients who failed first-line linezolid were assumed to switch to second-line vancomycin and vice versa. Therefore, in the absence of posthospitalization data, a time horizon of 4 weeks of an episode of NP caused by MRSA was adopted in line with the standard clinical practice mentioned above. In a separate study by De Cock et al. [16] , the same clinical consideration was applied with similar hospital lengths of stay of 28.1 days being reported for both study and comparator groups treated with linezolid and vancomycin, respectively. In addition, a local retrospective database analysis reported an average length of hospital stay of 23.8 days among 610 patients treated for NP in 13 tier-3A hospitals in China [22] . Furthermore, it is unlikely that there will be significant differences in terms of cost and effectiveness between two study groups upon recovery and discharge from hospitals. Fig. 1 -A decision-analytic model structure. AEs, adverse events; MRSA, methicillin resistance staphylococcus aureus; NP, nosocomial pneumonia.
We calculated the expected total inpatient costs and effectiveness over the time horizon of 4 weeks for linezolid and vancomycin. Effectiveness was defined as the probability of a patient being successfully treated, which was based on the treatment cure rates from a published trial [14] . The cost-effectiveness results in this study were presented as the incremental cost in terms of additional successfully treated patient for comparison between linezolid and vancomycin. In the case of linezolid, treatment results in, on average, a greater number of additional successfully treated patients at a lower overall estimated total inpatient cost and linezolid is considered dominant over vancomycin. 
ICER
Clinical Expert Panel
Given that most of the MRSA-confirmed NP cases in China are treated in tier-3A hospitals in which facilities such as intensive care units (ICUs) are available, a total of 25 clinical experts with experience in managing NP at major tier-3A hospitals in these four representative cities (Beijing, Guangzhou, Nanjing, and Xi'an) within the study scope were recruited and surveyed through a series of structured interviews. This physician sample represented four to six main tier-3A representative hospitals in each of these cities within the study scope. Recognizing the limitation of not including all the tier-3A hospitals in these cities in our sample, the effect of uncertainty surrounding the resource use and cost data inputs obtained through surveys in our study was assessed through a series of scenario analyses. Besides, in general, all the clinical experts agreed with the model structure, assumptions, and key data inputs given the similarity in local and overseas clinical practice in managing MRSA-confirmed NP cases as reflected in the model. The main antibiotic options in Chinese hospitals for treating MRSA confirmed NP are vancomycin and linezolid. In China, however, it is not a common clinical practice to switch patients receiving IV linezolid to oral linezolid even though their condition may allow for the switch. Therefore, this scenario was not included in the analysis. The clinicians also highlighted that given the quality concerns over the use of generic products, branded vancomycin would always be used, especially in critical clinical conditions such as NP. Hence, Vancocin CP was considered as the comparator to linezolid (Zyvox) for the cost-effectiveness analyses in this study. The model inputs for the remaining parameters such as efficacy and AEs were based on analyses reported in the Wunderink et al. [14] trial and its subsequent post hoc published analysis [20] .
Input parameters
Taking a relatively conservative approach, clinical success rates in the modified intention-to-treat patients at end of study reported in the Wunderink et al. [14] trial were used as estimates for the treatment success outcomes of linezolid and vancomycin in the model. In the Wunderink et al. trial, clinical success/cure was defined as resolution of clinical signs and symptoms of pneumonia; compared with baseline, improvement or lack of progression in chest imaging; and no requirement for additional antibacterial treatment. To prevent double counting, an overall mortality rate was considered over 4 weeks covering both the first-and second-line treatments using modified intention-totreat population-based weighted average 60-day mortality data reported in the Wunderink et al. [14] trial. Because most of the deaths happened during the first 30 days, the effect of using 60-day mortality data in this study was therefore assumed to be negligible compared with using 30-day data. In addition, given a lack of significant difference in 60-day mortality results between linezolid and vancomycin treatment groups in the Wunderink 
et al. [14] trial, same mortality rates were assumed for both the treatments. The study discontinuation rates due to severe AEs reported in the same trial were used to provide the probability of AEs leading to therapy switch in the model. Last, the probability of treatment failure among survivors was calculated as 1 -(probability of success þ probability of AEs þ probability of mortality).
Inputs from clinical experts were used to validate the resource utilization data (length of general ward and ICU stay) obtained from the post hoc analysis of the Wunderink et al. trial data [20] . The number of antibiotic treatment days ranges from 10 to 14 days for both linezolid and vancomycin. In general, for a clinical case similar to those patients investigated in the Wunderink et al. [14] trial, the expert panel suggested a range of 7 to 14 days of ICU stay followed by another week in the general ward. These estimates were close to the findings of 10.1 and 7.8 days, respectively, for linezolid and 10.6 and 8 days, respectively, for vancomycin reported from the post hoc analysis of Wunderink et al. trial data [20] .
Daily costs were averaged by city for hospital stay in a general ward and an ICU. These values were based on estimates provided by local clinical experts in reference to currently available annual or quarterly financial and admission figures of patients treated in ICUs of these hospitals. The total inpatient costs included drug acquisition, clinical consultations, nursing care, hospital bed, mechanical ventilation, IV administration and laboratory testing, and other ancillary costs, if any. Consistent drug acquisition costs were reported for a vial of 600 mg Zyvox and a vial of 500 mg Vancocin CP across four different cities. The input values for base-case analysis are given in Table 1 .
Scenario Analysis
The robustness of the cost-effectiveness results was further assessed by conducting a series of scenario analyses on parameters such as treatment duration, day of drug switch, inclusion of specific AEs, daily ICU cost, daily general ward cost, and drug and AE costs. On the basis of adverse rates observed in the Wunderink et al. [14] trial and the post hoc analysis [20] , we estimated and included the costs of managing common AEs such as renal failure (linezolid: 4.02% vs. vancomycin: 15.18%) and thrombocytopenia (linezolid: 16.3% vs. vancomycin: 13.2%) in the scenario analyses. Published average additional stay of 3.2 days in the ICU and 0.6 days in the general ward for renal failure [20] and an additional stay of 2.7 days in the general ward for drug-induced thrombocytopenia [23] were applied together with the average daily costs in the ICU and the general ward for different cities in the AE cost estimation.
A total of eight scenario analyses were evaluated in our analysis (Table 3) .
Results
Cost-Effectiveness Analysis
Considering both first-and second-line treatment strategies, the model estimated treatment success probability to be 0.629 and 0.602 for linezolid and vancomycin, respectively. Because of different daily costs for hospital stay in the general ward and the ICU, the estimated overall total inpatient costs for treatment starting with linezolid and vancomycin varied across the four cities. Based on the total hospital stay of 17.9 days and 18.6 days as reported for linezolid and vancomycin, respectively [20] , overall total inpatient costs ranging from ¥58, 390 in Xi'an to ¥87, 033 (Table 2) in Guangzhou were estimated by the adapted model. Linezolid was estimated to have greater effectiveness in successfully treating patients (by 0.027 or 2.7%) and lower total inpatient costs (by ¥139) resulting in a "dominant" treatment option (with a higher probability of treatment success and a lower total treatment cost) compared with vancomycin for the Guangzhou region scenario. In contrast, for Beijing, Nanjing, and Xi'an, the ICERs in terms of additional successfully treated patient were estimated at ¥1,861, ¥163, and ¥16,509, respectively (Table 2) .
Scenario Analysis
Based on the expert panel's opinions, a series of scenario analyses were conducted by varying the values of resource utilization and unit costs. The ICERs in terms of additional successfully treated patient for each scenario are given in Table 3 for the context of four different cities. Dominance of linezolid over vancomycin was observed in most of the scenario analyses for Beijing, Guangzhou, and Nanjing. The total inpatient 
16,509
ICER, incremental cost-effectiveness ratio; Lin, linezolid; Van, vancomycin.
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cost difference between linezolid and vancomycin increased, resulting in a higher ICER when the switch to second line due to first-line failure or AEs was accelerated from day 7 to day 3. As expected, the ICERs (for using linezolid over vancomycin) increased as the per day total costs in the general ward and the ICU reduced, providing less cost offset attributed to shorter hospital stay as reported for treatment with linezolid. The same was observed in ICERs in the scenarios of lower drug acquisition cost of Vancocin CP, resulting in higher incremental total inpatient costs for using linezolid over vancomycin. Xi'an regional analysis observed a similar trend because of lower hospital stay unit costs that were reported for tier-3A hospitals as compared with those in other cities. An additional scenario of removal of hospital margin of 13% on drug costs as part of the national health care reform by the National Development and Reform Commission of People's Republic of China [24] was tested for the drug acquisition cost of a vial of 600 mg Zyvox and a vial of 500 mg Vancocin CP at ¥400 and ¥125, respectively. Dominance by linezolid over vancomycin was observed in this scenario for Beijing, Guangzhou, and Nanjing except Xi'an with an ICER of ¥7, 810 for each additional successfully treated patient.
Discussion
NP caused by MRSA places a substantial economic burden on the hospital through the use of health care resources. Although linezolid had a higher drug acquisition cost, it provided greater efficacy and resulted in lower inpatient medical costs due to less resource use, for example, shorter ICU and general ward stays and therefore a total inpatient cost saving against vancomycin. Because of differences in cost per day of hospitalization (general ward and ICU) across the four cities, the estimated total inpatient costs for treatment with linezolid and vancomycin varied among these cities. Costs of ICU and general ward stay in Xi'an were found to be lower than those reported for other cities. The overall total inpatient costs (¥58,390-¥87,033), estimated by the adapted model for these cities for hospital stays of 17.9 days and 18.6 days, are likely to be conservative in comparison to the reported average total inpatient cost of ¥108,950 over an average hospital stay of 23.8 days published in a retrospective database analysis of 597 hospital-acquired pneumonia cases across 13 tier-3A hospitals in nine cities in China [22] . This reported figure, however, also included data of all other hospital-acquired pneumonia cases, not limited to only MRSA confirmed NP cases.
As the Wunderink et al. [14] trial showed that linezolid presented higher efficacy resulting in lower health resource utilization, linezolid was more efficacious in patients with MRSA confirmed NP, offering an advantage in terms of both clinical cure rate and AE rate such as renal toxicity [25, 26] . Using the superior efficacy data reported from the head-to-head Wunderink et al. [14] trial, resource utilization data from the post hoc analysis [20] , and local unit costs, our base-case results of dominance by linezolid and relatively low ICERs of less than ¥20,000 in terms of additional successfully treated patient suggest that linezolid is likely to be a cost-effective option compared with branded vancomycin in the contexts of four cities in China. The 2012 AEs, adverse events; BJ, Beijing; ER, emergency room; GW, general ward; GZ, Guangzhou; ICER, incremental cost-effectiveness ratio; ICU, intensive care unit; Lin, linezolid; NJ, Nanjing; XN, Xi'an. * Estimated total in-patient costs due to drug-induced renal failure: ¥21,316 (BJ), ¥24,546 (GZ), ¥21,968 (NJ), and ¥15,615 (XN). † Estimated total in-patient costs due to drug-induced thrombocytopenia: ¥2,322 (BJ), ¥2,457 (GZ), ¥2,376 (NJ), and ¥1,868 (XN). ‡ Increase or reduction in the corresponding cost from those considered in the base-case analysis.
gross domestic product per capita figures reported for these four cities are in the region of ¥51,000 for Xi'an to ¥106,000 for Guangzhou [27] . The cost-effectiveness results of linezolid were further confirmed by the resulting ICERs in a series of scenario analyses that evaluated the uncertainty in resource use and cost inputs. Dominance by linezolid was also observed for Beijing, Guangzhou, and Nanjing in a likely scenario of removing 13% margin on drug costs by the hospitals as part of the health care reform by the National Development and Reform Commission of People's Republic of China. In the same scenario, the ICER reduced from ¥16,509 to ¥7,810 for Xi'an. In a separate scenario analysis of inclusion of costs in managing AEs such as renal failure and thrombocytopenia using the resource use data reported in post hoc analysis of the Wunderink et al. [20] trial, dominance over vancomycin by linezolid was demonstrated across all four cities. In summary, as shown in the results of scenario analyses (Table 3 ), parameters such as treatment duration, inclusion of cost of managing AEs, and drug acquisition costs are the main drivers presenting the most uncertainty to the cost-effectiveness results. We believe that the resulting ICERs, for both base-case and scenario analyses, in this study are conservative. For example, based on the expert opinions, laboratory facility of measuring serum vancomycin is not common among the tier-3A hospitals in China; therefore, without proper monitoring and adjustment of vancomycin dosing regimen in these critically ill patients, the renal toxicity rates based on the Wunderink et al. trial are likely to be conservative for the local contexts in China. This means for additional costs to manage higher rates of vancomycin-induced toxicities, the ICERs would be lower than what have been estimated in this study, further confirming that linezolid is more cost-effective than branded vancomycin in treating patients with MRSA confirmed NP in China. On a separate but relevant note, reduction in total per-patient hospital costs has been shown to be associated with the use of linezolid in a number of published studies [28, 29] .
Furthermore, in the absence of published efficacy data of linezolid and vancomycin as a second-line treatment, it is a conservative approach to assume and apply the same efficacy reported in the Wunderink et al. trial [14] in which both these drugs were compared and investigated as a first-line treatment. We believe that the efficacy of these drugs as a second-line treatment might be lower, particularly for those who failed either linezolid or vancomycin as their first-line treatment. Pertinent to this discussion, a recent study by Mullins et al. [30] concluded that the likelihood of a rehospitalization among adult patients treated for infection was lower in both absolute and relative terms for those treated with linezolid versus vancomycin. In addition, the benefit of switching from IV to oral formulation resulting in a shorter duration IV therapy and hence lower administration costs and earlier hospital discharge was not taken into account in our analysis. Such benefit has been demonstrated in the cost-effectiveness studies carried out in various countries [21, 29, 31, 32] . Also, the potential work productivity gain through early discharge from a shorter hospital stay for patients treated with linezolid was not captured in our model. In view of all the above considerations, the ICERs reported in this study may have been overestimated.
Several limitations should be taken note of while interpreting our findings. First, local cost data that are derived from appropriately sampled patient-level data of each hospital would be ideal as the model inputs. This still remains a challenge, however, to conduct health service research in most of the developing countries including China. Therefore, we aimed to address this limitation by conducting a series of scenario analyses to evaluate the effect of uncertainty around the local cost inputs on the costeffectiveness results of this study. Second, cost-effectiveness results would tend to be interpreted in terms of incremental cost per quality-adjusted life-year against a recommended threshold such as one to three times the gross domestic product per capita by the World Health Organization [33] . Further research is suggested to include the quality-of-life data to allow analysis in incremental cost per quality-adjusted life-year gained. Another limitation of our model is the short time horizon of 4 weeks in which lifetime resource use and benefits, if any, might have been missed in the current analysis. Therefore, it is recommended to consider all the above in the future cost-effectiveness analysis of linezolid in treating MRSA confirmed NP. It is worth, however, highlighting that given patients with NP are generally older, suffering from numerous comorbidities that may complicate treatment, and have factors that put them at a higher risk of acquiring mixed infection, the findings in a cost-effectiveness study in MRSA confirmed NP may not be generalized across different health care settings and need to be interpreted with caution.
To our knowledge, this study is the first cost-effectiveness analysis for MRSA confirmed NP in a Chinese setting using the recent head-to-head linezolid versus vancomycin trial data reported in Wunderink et al. [14] . Thus, it would be interesting to investigate and compare the results of previous costeffectiveness analyses against those using the same models but based on the data reported in the Wunderink et al. [14] trial.
Conclusions
Despite a higher direct drug acquisition cost of linezolid in China, our analyses suggest that, given its superior efficacy and outcomes, linezolid is likely a cost-effective alternative for the firstline treatment of MRSA confirmed NP as compared with branded vancomycin from the local payer perspectives of Beijing, Guangzhou, Nanjing, and Xi'an.
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